GlassScriptPhysician profile
Jacqueline Owen
NPI 1215171608
$4,050.60
in general payments reported to CMS, 2019-2025
23 companies · $1,917 in 2025
The $1,917 reported for 2025 was more than what 92% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $625 · 2024: $1,508 · 2025: $1,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,050.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $578.56 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Axsome Therapeutics, INC. | $473.85 | 2023-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $459.21 | 2023-2025 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $422.05 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $320.12 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $315.31 | 2023-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $275.08 | 2023-2025 | Ingrezza |
| Lundbeck LLC | $214.10 | 2023-2025 | Rexulti |
| Braeburn INC. | $182.46 | 2025 | Brixadi |
| Vanda Pharmaceuticals INC. | $162.00 | 2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $148.71 | 2025 | Cobenfy |
| Eisai INC. | $97.68 | 2024 | |
| Bausch Health US, LLC | $90.47 | 2024-2025 | Aplenzin, Wellbutrin |
| Abbvie INC. | $85.29 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.90 | 2025 | Trintellix |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $36.72 | 2025 | Wegovy |
| Almatica Pharma LLC | $35.50 | 2024-2025 | Loreev Xr |
| Noven Therapeutics, LLC | $23.06 | 2024 | Xelstrym |
| Idorsia Pharmaceuticals US INC | $17.56 | 2024 | Quviviq |
| Lilly USA, LLC | $16.98 | 2025 | Mounjaro, Zepbound |
| Brainsway USA INC | $15.94 | 2025 | Deep Tms System |
| Indivior INC. | $15.84 | 2024 | Sublocade |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.21 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Owen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.